SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...

Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Combining ...

The efficacy of transarterial techniques can be assessed in terms of imaging response (CT scan), biologic response (AFP), degree of tumor necrosis, patient survival or quality of life. The most ...

AstraZeneca announces IMFINZI plus TACE and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

Transcatheter arterial chemoembolization alone and with microwave ablation yielded comparable overall survival rates in patients with recurrent small hepatocellular carcinoma after resection, per ...

SAN FRANCISCO — Adding transarterial chemoembolization (TACE) to treatment with lenvatinib (Lenvima) significantly improved survival compared to levantinib alone in patients with advanced ...